Catalog No.
Product Name
Application
Product Information
Citations
-
β-catenin:β-TrCP Interaction Enhancer
NRX-2663 is an enhancer of the β-catenin:β-TrCP interaction, specifically targeting the binding of β-catenin to its E3 ubiquitin ligase, SCFβ-TrCP. This compound improves the affinity of β-catenin peptides for β-TrCP, demonstrating an EC50 of 22.9 μM and a Kd of 54.8 nM. NRX-2663 is valuable for research into the regulation of the Wnt signaling pathway and its implications in various cancers and developmental processes. -
β-catenin/Tcf PPI Inhibitor
β-catenin-IN-37 is a selective inhibitor of the β-catenin/T-cell factor (Tcf) protein-protein interaction. This compound effectively disrupts canonical Wnt signaling, exhibiting inhibitory activity against colorectal cancer cell lines SW480 and HCT116, with IC50 values of 20 μM and 31 μM, respectively. β-catenin-IN-37 is valuable for studying Wnt signaling pathways and their implications in cancer research. -
Wnt/β-Catenin Inhibitor
YW1128 is a potent Wnt/β-Catenin inhibitor that induces the proteasomal degradation of β-catenin, leading to the inhibition of Wnt/β-Catenin signaling pathways in cells. This compound significantly reduces hepatic lipid accumulation and enhances glucose tolerance in mice subjected to a high-fat diet, demonstrating an absence of noticeable toxicity. Furthermore, YW1128 downregulates genes associated with glucose and fatty acid anabolism, making it a valuable tool for research into metabolic disorders and Wnt signaling pathway modulation. -
β-catenin/TCF Signaling Inhibitor
CCT031374 hydrobromide is a potent inhibitor of the β-catenin/TCF signaling pathway. It effectively disrupts TCF-dependent transcription of target genes associated with the Wnt signaling cascade. CCT031374 demonstrates significant antitumor activity, making it valuable for research in cancer biology and therapeutic development targeting aberrant Wnt signaling. -
GSK3β Inhibitor
GSK3β-IN-2 is a potent GSK3β inhibitor with an IC50 of 0.35 nM. This compound activates the Wnt/β-catenin signaling pathway, leading to enhanced neurogenesis and neurite outgrowth. Additionally, GSK3β-IN-2 effectively inhibits Aβ-induced tau hyperphosphorylation at Ser396 and reduces neurofibrillary tangle formation. Its efficacy in ameliorating Alzheimer's disease has been demonstrated in zebrafish models, making it a valuable tool for neurological research. -
β-catenin Inhibitor
CGK012 is a selective β-catenin inhibitor that disrupts the Wnt/β-catenin signaling pathway. It effectively inhibits the release of HMGB1 and the transcriptional activity of β-catenin, demonstrating potential therapeutic benefits in sepsis induced by cecal ligation and puncture as well as in multiple myeloma. This compound is valuable for research applications focused on Wnt signaling regulation and its implications in various diseases. -
β-Catenin Modulator
Pin1 modulator 1 (compound IIb-219) serves as a selective inhibitor of β-Catenin, effectively modulating the Wnt signaling pathway. This compound demonstrates potential utility in researching Wnt-related diseases, notably in cancer studies, where aberrant activation of the Wnt pathway is implicated in tumorigenesis. Its role as a β-Catenin modulator enables detailed investigations into therapeutic strategies targeting these critical biological processes. -
CBP/β-catenin Antagonist
C-82 is a selective antagonist of CBP/β-catenin interaction, designed to inhibit the binding of β-catenin to CBP while promoting its association with p300. This compound effectively modulates the Wnt signaling pathway, making it a valuable tool for research in cancer biology and developmental processes. C-82 serves as an important reagent for studies investigating the role of β-catenin in transcriptional regulation and related disease mechanisms. -
PTK7/β-catenin Inhibitor
PTK7/β-catenin-IN-1 is a selective inhibitor targeting the PTK7/β-catenin signaling pathway, demonstrating an IC50 of 8.9 μM for PTK7/β-catenin and 56.5 μM for p53/MDM2. This compound shows promise in cancer research, particularly in studies examining the modulation of tumorigenic pathways influenced by β-catenin. Its inhibitory effects provide a valuable tool for investigating the role of PTK7 in cancer progression and therapeutic strategies. -
PTK7/β-catenin Inhibitor
PTK7/β-catenin-IN-6 is a selective inhibitor of the PTK7/β-catenin interaction, effectively disrupting the Wnt signaling pathway. This compound demonstrates significant anticancer activity, particularly in colorectal cancer (CRC) models, making it a valuable tool for cancer research and therapeutic studies targeting Wnt-related pathways. -
β-catenin Inhibitor
β-catenin-IN-4 is a potent inhibitor of β-catenin, exhibiting an inhibition constant (Ki) of 0.64 μM. This compound effectively decreases the protein expression levels of key oncogenic factors such as cyclin D1 and c-Myc. β-catenin-IN-4 is valuable for research applications focused on cancer biology, particularly in studies investigating the Wnt signaling pathway and its role in tumor progression. -
Wnt/β-catenin Signaling Pathway Inhibitor
Wnt/β-catenin-IN-2 is an inhibitor of the Wnt/β-catenin signaling pathway, displaying an IC50 value of 7.1 μM and a KD value of 2.5 μM. This compound is useful in cancer research, enabling the study of Wnt/β-catenin pathway modulation and its implications in tumorigenesis. Its application can enhance understanding of the mechanistic roles of this pathway in various malignancies. -
Wnt/β‐Catenin Activator
N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a macamide derived from Maca (Lepidium meyenii Walp.) that acts as a Wnt/β-catenin activator. This compound promotes the osteogenic differentiation of mesenchymal stem cells and enhances bone formation by activating the canonical Wnt/β-catenin signaling pathway. It serves as a valuable reagent for research focused on osteoporosis and related conditions. -
β-catenin Inhibitor
β-catenin-IN-6 is an inhibitor of β-catenin, effectively disrupting the canonical Wingless-related integration site signaling pathway. This compound demonstrates significant anti-proliferative effects on human colorectal cancer cells and has been shown to inhibit tumor growth in a β-catenin/RK3E mouse model, making it a valuable reagent for cancer research and therapeutic studies targeting β-catenin signaling pathways. -
β-catenin/BCL9 Complex Inhibitor
E722-2648 is a selective inhibitor of the β-catenin/BCL9 complex, targeting the interaction between these two proteins to inhibit β-catenin-mediated transcriptional activity. This compound demonstrates significant antitumor activity by downregulating the expression of WNT target genes, effectively suppressing tumor growth in colon cancer xenograft and colorectal cancer mouse models. E722-2648 serves as a valuable tool for investigating the molecular mechanisms of colon and colorectal cancers. -
Wnt Inhibitor
PTK7/β-catenin-IN-2 is a potent inhibitor of the PTK7/β-catenin interaction, effectively disrupting Wnt/β-catenin signaling with an IC50 of 5.6 μM. This inhibition impairs cell growth mediated by the Wnt pathway and demonstrates potential anticancer activity. Additionally, PTK7/β-catenin-IN-2 exhibits inhibitory effects on the p53-MDM2 interaction, with an IC50 of 157.1 μM, making it valuable for research focused on cancer therapies and signaling pathway modulation. -
GSK-3 Inhibitor
Laduviglusib dihydrochloride is a selective inhibitor of glycogen synthase kinase-3 (GSK-3), an enzyme involved in numerous cellular processes including glycogen synthesis, cell differentiation, and apoptosis. By inhibiting GSK-3, Laduviglusib dihydrochloride promotes cell survival and has been extensively studied in the context of neurodegenerative diseases, diabetes, and cancer research. This compound serves as a valuable tool for elucidating the role of GSK-3 in various signaling pathways and therapeutic applications. -
β-catenin synthesis reducer
Surbisiran is a small interfering RNA (siRNA) that functions as a β-catenin synthesis reducer. By inhibiting the synthesis of β-catenin, it exhibits antineoplastic activity, making it a valuable tool for cancer research. Surbisiran can be utilized to explore the role of β-catenin in various malignancies and investigate therapeutic strategies targeting this pathway. -
Wnt/β-catenin Agonist
SLD1121 is a potent agonist of the Wnt/β-catenin signaling pathway, specifically targeting LRP6 with an inhibition constant (Kd) ranging from 4.52 to 7.49 nM. By interacting with the intracellular domain of LRP6, SLD1121 stabilizes the receptor, enhances its nuclear translocation, and promotes its association with β-catenin, TCF4, or LEF1, leading to the upregulation of Wnt-regulated and stem cell-associated genes. Notably, SLD1121 facilitates the transition of hair follicles from the telogen to anagen phase in the mouse hair growth cycle, making it a valuable reagent for research focused on hair loss and regenerative medicine. -
β-Catenin Antagonist
aStAx-35R is a stapled peptide that functions as a β-catenin antagonist targeting the nuclear form of β-catenin to disrupt Wnt signaling pathways. By competitively inhibiting the binding of β-catenin to TCF4, aStAx-35R effectively induces growth inhibition in Wnt-dependent cancer cell lines. This compound presents valuable potential for research applications focused on cancer biology and therapeutic strategies targeting the Wnt/β-catenin signaling pathway. -
Wnt/β-catenin Signal Inhibitor
KP-6 is a polypeptide that acts as a Wnt/β-catenin signaling pathway inhibitor. By inhibiting TGF-β, KP-6 disrupts critical fibrotic signaling pathways in vivo, effectively reducing renal tissue damage and fibrotic progression. This compound holds promise for research focused on chronic kidney disease (CKD) and other fibrosis-related disorders, making it a valuable tool for studying disease mechanisms and potential therapeutic interventions. -
Wnt/β-catenin Inhibitor
Wnt/β-catenin-IN-5 is a potent inhibitor of the Wnt/β-catenin signaling pathway. This compound demonstrates significant inhibition of cell proliferation in HCT 116, SW480, and A549 cell lines, with IC50 values of 3.05 μM, 3.27 μM, and 34.91 μM, respectively. It serves as a valuable tool for research focused on cancer biology and the role of Wnt signaling in tumor development and progression. -
GSK3β Inhibitor
BRD1172 is a selective inhibitor of glycogen synthase kinase 3 beta (GSK3β), exhibiting an IC50 of 24 nM. This compound effectively inhibits GSK3β-mediated Tau phosphorylation in SH-SY5Y cells and alleviates the negative regulation of GSK3β on β-catenin degradation and TCF/LEF promoter activity. BRD1172 is applicable in research related to Alzheimer’s disease, cardiac hypertrophy, and various cancers. -
β-catenin:TCF Interaction Inhibitor
β-Catenin inhibitory peptoid targets the β-catenin:TCF interaction, exhibiting an IC50 of 5.44 µM. This compound effectively inhibits Wnt signaling with an IC50 of 0.105 µM and androgen receptor signaling with an IC50 of 1.02 µM in prostate cancer cell lines. The peptoid significantly reduces cell proliferation, making it a valuable tool for research in cancer biology and therapeutic development. -
Wnt/β-catenin Inhibitor
Wnt/β-catenin-IN-3 is a potent inhibitor of the Wnt/β-catenin signaling pathway, demonstrating low micromolar GI50 values across various cancer cell lines. This compound induces G2/M cell cycle arrest by activating the p53-p21 pathway and promotes apoptotic cell death through both intrinsic and extrinsic mechanisms in colon cancer cells. It serves as a valuable tool for investigating the role of Wnt/β-catenin signaling in cancer biology and therapeutic applications. -
β-catenin Inhibtior
β-catenin-IN-8 is a potent inhibitor of β-catenin, targeting the Wnt signaling pathway. This compound effectively reduces the levels of β-catenin and c-Myc proteins, leading to downregulation of Wnt-target genes such as Fgf20 and Sall4. β-catenin-IN-8 exhibits anti-cancer activity in colorectal cancer models and demonstrates favorable metabolic stability, making it a valuable tool for research into cancer biology and therapeutic strategies. -
Wnt/β-catenin Inhibitor
Getacatetide is a peptide-based inhibitor of the Wnt/β-catenin signaling pathway. This compound is designed to interfere with the activation of Wnt target genes, making it a valuable tool for investigating the role of Wnt/β-catenin signaling in solid tumors. Getacatetide's ability to disrupt this pathway facilitates research into cancer biology and the development of potential therapeutic strategies. -
Wnt Inhibitor
Halofenate acts as a Wnt inhibitor, impacting the Wnt signaling pathway crucial for cell proliferation and differentiation. It demonstrates significant biological activity by effectively reducing serum triglyceride levels by 50% in hypertriglyceridemic patients and decreasing serum uric acid by 30%, highlighting its potential uricosuric effects. Halofenate additionally increases plasma thyroxine (T4) levels, suggesting implications for thyroid function regulation, supported by in vitro studies showing its ability to displace T4 from thyroid-binding proteins. This compound can be valuable for research into metabolic disorders and thyroid function modulation. -
β-Catenin Modulator
β-Catenin modulator-5, a selective modulator of β-Catenin, exhibits potent activity in regulating this key signaling pathway involved in cell proliferation and differentiation. This compound, characterized by its oxazole and thiazole structure, is valuable for research applications focused on cancer biology, developmental processes, and tissue homeostasis. Its ability to effectively manipulate β-Catenin activity makes it a crucial tool for investigating Wnt signaling-related mechanisms in various biological systems. -
β-Catenin Modulator
β-Catenin modulator-3 is a selective modulator of β-Catenin, characterized by its unique oxazole and thiazole chemical structure. This compound demonstrates significant biological activity in regulating β-Catenin signaling pathways, making it a valuable tool for research in cancer biology and developmental studies. Its ability to modulate the Wnt/β-Catenin pathway positions it as a potential candidate for studies targeting various cancers and neurodegenerative diseases. -
Axin Phosphorylation Inhibitor; β-catenin Phosphorylation Inhibitor
FRATtide is a peptide inhibitor targeting GSK-3, effectively disrupting the phosphorylation of Axin and β-catenin. By preventing the binding of GSK-3 to Axin, FRATtide modulates the Wnt signaling pathway, making it a valuable tool for research in cancer biology and developmental processes. This reagent is essential for studying mechanisms of β-catenin regulation and its implications in various diseases. -
β-Catenin Modulator
β-Catenin modulator-7 is a targeted modulator of β-catenin, primarily influencing its expression in the cytoplasm and nucleus of HCT-116 cells. This compound effectively inhibits GSK 3β phosphorylation, promoting nitric oxide release and thereby reducing cancer cell proliferation with an IC50 of 0.6-0.9 μM. β-Catenin modulator-7 is positioned for research applications in studying colon cancer and its associated signaling pathways. -
Wnt Inhibitor
Jatrophone is a diterpenoid that functions as a Wnt inhibitor, exhibiting significant anticancer activity. Isolated from Jatropha isabelli, Jatrophone disrupts the Wnt/β-catenin signaling pathway, leading to a reduction in cell proliferation and inhibition of epithelial-mesenchymal transition (EMT) in triple-negative breast cancer cells. This compound is valuable for research focused on cancer biology and therapeutic strategies targeting Wnt pathway modulation. -
β-catenin Inhibitor
NLS-StAx-h is a selective β-catenin inhibitor designed to disrupt Wnt signaling pathways. This cell-permeable, stapled peptide exhibits an IC50 of 1.4 μM, effectively blocking β-catenin-transcription factor interactions. NLS-StAx-h demonstrates potent anti-proliferative effects on cancer cells, making it a valuable tool for research in cancer biology and therapeutic applications targeting aberrant Wnt signaling. -
GSK-3β Inhibitor
GSK-3β inhibitor 24 is a highly potent inhibitor of glycogen synthase kinase 3 beta (GSK-3β), exhibiting an IC50 of 0.22 nM. This compound effectively enhances GSK-3β phosphorylation at the Ser9 site in a dose-dependent manner, while reducing hyperphosphorylation of tau protein, specifically lowering p-tau-Ser396 levels. Additionally, GSK-3β inhibitor 24 promotes the upregulation of β-catenin and neurogenesis-related markers such as GAP43 and MAP-2, making it a valuable tool in Alzheimer's disease research and therapeutic studies. -
β-Catenin Modulator
β-Catenin modulator-4 is a selective modulator of the β-Catenin signaling pathway. It exhibits strong potency in regulating β-Catenin activity, making it valuable for studies of cellular processes such as proliferation and differentiation. This compound is particularly relevant for research on developmental biology, cancer, and tissue regeneration, where β-Catenin plays a critical role in signaling dynamics. -
Wnt/β-Catenin Inhibitor
YW2036 is a potent inhibitor of the Wnt/β-Catenin signaling pathway, exhibiting an IC50 value of 637 nM. This compound has significant biological activity and is primarily utilized in research focused on colorectal cancer (CRC). Its role as a Wnt/β-Catenin inhibitor makes it a valuable tool for studies investigating the mechanisms underlying CRC progression and treatment approaches. -
β-catenin/Tcf4 Inhibitor
BC21 (NSC 109268) is a β-catenin/Tcf4 inhibitor with an IC50 of 5 μM. It disrupts the interaction between β-catenin and Tcf4-derived peptides, thereby inhibiting β-catenin/Tcf4-mediated transcriptional activity. This compound is particularly valuable in cancer research, where aberrant β-catenin signaling plays a critical role in tumor progression. -
Wnt/β-catenin Inhibitor
hsBCL9CT-24 is a potent inhibitor of the Wnt/β-catenin signaling pathway, targeting β-catenin to modulate oncogenic processes. This compound has demonstrated significant anti-tumor activity by reactivating the anti-cancer immune response impaired by aberrant Wnt signaling. hsBCL9CT-24 is applicable in cancer research, particularly in studies exploring Wnt pathway inhibition and immune evasion in tumor microenvironments. -
β-Catenin Modulator
β-Catenin modulator-2 is a selective modulator of β-Catenin, primarily targeting the Wnt signaling pathway. This compound, characterized by its oxazole and thiazole structure, exhibits significant biological activity in regulating β-Catenin levels. It is suitable for research applications aimed at studying cellular processes involved in cancer, developmental biology, and tissue regeneration. -
β-Catenin Modulator
β-Catenin modulator-1 (IIa-650) is a potent modulator of β-Catenin, a crucial component in the Wnt signaling pathway. It demonstrates significant biological activity in the regulation of cell proliferation and differentiation, making it invaluable for cancer research. This compound is utilized to investigate β-Catenin's role in tumorigenesis and other related pathologies, providing insights into therapeutic strategies targeting this pathway. -
Wnt/β-catenin Inhibitor
1(R),2(S)-epoxy Cannabidiol is a potent inhibitor of the Wnt/β-catenin signaling pathway. This structural analogue of phytocannabinoids demonstrates significant biological activity, making it a valuable tool for research in neuroprotection. Its ability to modulate this critical pathway positions it as a promising candidate for studies focused on neuroprotective agents. -
β-catenin/Tcf4 Inhibitor
Murayaquinone is a potent inhibitor of the β-catenin/Tcf4 complex, exhibiting an IC50 of 2.4 μM. This compound, derived from Streptomyces sp. AN140557, demonstrates significant nematicidal activity. It serves as a valuable tool for research applications focused on Wnt signaling pathways and their roles in developmental biology and cancer research. -
β-Catenin Modulator
β-Catenin modulator-8 is a small molecule that functions as a β-Catenin modulator, primarily targeting the Wnt signaling pathway. It exhibits significant potential in altering β-Catenin activity, making it a valuable tool for research in cancer biology. This compound can be utilized in studies aimed at understanding tumorigenesis, as well as in the development of therapeutic strategies targeting β-Catenin-related malignancies. -
Wnt/β-catenin Inhibitor
Sempervirine nitrate is a Wnt/β-catenin pathway inhibitor derived from the alkaloid Gelsemium elegans Benth. This compound exhibits significant anti-proliferative effects on hepatocellular carcinoma (HCC) cells and promotes apoptosis through modulation of the Wnt/β-catenin signaling cascade. Sempervirine nitrate is valuable for research into cancer biology and therapeutic approaches targeting HCC. -
β-catenin Modulator
β-Catenin modulator IIa-661 is a selective modulator of β-catenin, targeting its activity and inhibiting the Wnt/wingless (wg) signaling pathway. This compound is instrumental in cancer research, providing insights into β-catenin's role in tumor progression and cellular signaling. Its application may aid in developing therapeutic strategies for cancers characterized by aberrant Wnt signaling. -
GSK-3α/β Selective Inhibitor
GSK-3α/β-IN-1 is a selective inhibitor of glycogen synthase kinase-3 alpha and beta (GSK-3α/β), demonstrating IC50 values of 0.265 μM for GSK-3α and 0.255 μM for GSK-3β. Additionally, GSK-3α/β-IN-1 exhibits PKA inhibition with an IC50 of 0.188 μM. This compound effectively reduces cell viability in several glioblastoma (GBM) cell lines, with IC50 values ranging from 3 to 6 μM over 72 hours, while displaying minimal toxicity to human astrocytes. GSK-3α/β-IN-1 also shows promising central nervous system activity in human blood-brain barrier models of GBM, supporting its potential as a therapeutic agent in cancer research. -
PKG/PKA Activator
Sp-8-pCPT-cGMPS is a potent activator of protein kinase G (PKG) and protein kinase A (PKA) with significant cell membrane permeability and phosphodiesterase stability. This cyclic guanosine monophosphate analog effectively engages PKG types I α, I β, and II, making it invaluable for research in signal transduction pathways. It is utilized to investigate the role of cGMP in neural plasticity, synaptic transmission, and other physiological processes influenced by these kinases. -
γ-Secretase Inhibitor
EVP-0015962 is a potent γ-secretase inhibitor that effectively penetrates the blood-brain barrier, exhibiting an IC50 value of 3.9 μM. By modulating the γ-secretase-mediated cleavage of amyloid precursor protein, EVP-0015962 decreases the production of Aβ42 while increasing Aβ38 levels. This compound has demonstrated efficacy in reducing amyloid aggregates, mitigating amyloid plaque formation, and lowering inflammatory markers in mouse models, thereby enhancing cognitive function. EVP-0015962 serves as a valuable tool in Alzheimer's disease research. -
γ-Secretase Modulator
AZ1136 is a selective γ-secretase modulator (GSM) that effectively reduces the levels of amyloid-beta peptides Aβ42 and Aβ40, with IC50 values of 990 nM and 1400 nM, respectively. Furthermore, AZ1136 increases levels of Aβ39 and Aβ37 while showing no effect on Aβ38. This compound is valuable for research applications investigating the pathogenesis of Alzheimer's disease and the modulation of amyloid-beta metabolism.
